Task V08: Process Development for Scale-up of Vero Cells on Micro-Carriers for Manufacturing of a Live-Attenuated RSV Vaccine

任务 V08：用于生产 RSV 减毒活疫苗的微型载体上 Vero 细胞放大的工艺开发

• 批准号: 10329660
• 负责人: ARBELO CRISTINA
• 金额: $ 6.75万
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-15 至 2028-05-14
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10329660
• 关键词: Adjuvant; Attenuated; Biological; Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Emerging Communicable Diseases; Phase; Process; Respiratory Syncytial Virus Vaccines; Services; System; United States Food and Drug Administration; Vaccines; Vero Cells; novel vaccines; product development; scale up; vaccine delivery; vaccine development

The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism, and emerging and re-emerging infectious diseases. This contract also provides for manufacture of vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.

传染病疫苗和其他生物制剂的生产和表征服务（MCS）合同提供各种服务，包括产品开发规划和可行性评估;产品优化;产品开发和I/II期临床研究的cGMP合规生产;技术和设施审计;以及适用于提交给美国食品药品监督管理局（FDA）的监管支持。 这些服务将有助于开发和引进新的疫苗和生物制剂，以对付潜在的生物恐怖主义制剂以及新出现和重新出现的传染病。 该合同还规定了疫苗、疫苗成分（包括佐剂）、疫苗输送系统、其他生物制剂和攻毒材料的生产。